CompanyGraphMedprin Regenerative Medical Technologies Inc.
301033 · SZSE · China
medprin.comFinancials as of FY2025
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- PositionOperating margin is 39.4%, higher than 95% of its Medical Devices peers (median 7.3%)
- Interpretations10 currently firing — 10
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.31%
Annual Rate
CNY 0.70Paid annual
Payout Ratio
38.5%Sustainable
Payback Period
76.5 yr
Last Ex-Dividend
Jun 1, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.60BCNY535.91M · vs all stocks (USD)
Trailing P/E
29.51xvs Medical Devices peers
Revenue (TTM)
400.85MCNY59.62M · vs all stocks (USD)
Profit Margin
30.54%vs Medical Devices peers
52-Week Change
-33.10%vs all stocks
Market Capitalization
3.60BCNY535.91M · vs all stocks (USD)
Enterprise Value
3.29BCNY489.07M · vs all stocks (USD)
Trailing P/E
29.51xvs Medical Devices peers
Price to Sales (TTM)
8.99xvs Medical Devices peers
Price to Book (MRQ)
4.39xvs Medical Devices peers
Enterprise to Revenue
8.20xvs Medical Devices peers
Enterprise to EBITDA
21.01xvs Medical Devices peers
Gross Margin
78.77%vs Medical Devices peers
Profit Margin
30.54%vs Medical Devices peers
Operating Margin
39.35%vs Medical Devices peers
Return on Assets (TTM)
9.55%vs Medical Devices peers
Return on Equity (TTM)
16.02%vs Medical Devices peers
Revenue (TTM)
400.85MCNY59.62M · vs all stocks (USD)
Revenue per Share (TTM)
6.06CNYUpdated Aug 29, 2026Quarterly Revenue Growth
32.50%vs Medical Devices peers
Gross Profit (TTM)
315.95MCNY46.99M · vs all stocks (USD)
EBITDA (TTM)
156.37MCNY23.26M · vs all stocks (USD)
Net Income (TTM)
122.41MCNY18.21M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
55.00%vs Medical Devices peers
Operating Cash Flow (TTM)
131.55MCNY19.57M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
62.71MCNY9.33M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.7000CNYUpdated Aug 29, 2026Trailing Annual Dividend Yield
1.31%vs all stocks
Payout Ratio
38.46%vs Medical Devices peers
Revenue
368.83MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
72.92MCNYFY2025 · Dec 31, 2025Gross Profit
295.91MCNYFY2025 · Dec 31, 2025Operating Income
126.94MCNY18.88M · vs all stocks (USD)
Pre-tax Income
126.17MCNYFY2025 · Dec 31, 2025Income Tax Expense
13.04MCNYFY2025 · Dec 31, 2025Net Income
113.13MCNYFY2025 · Dec 31, 2025EBIT
126.19MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
156.37MCNYFY2025 · Dec 31, 2025Research & Development
36.96MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
50.07MCNYFY2025 · Dec 31, 2025Other Operating Expenses
6.75MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
1.58MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
19.72KCNYFY2025 · Dec 31, 2025EPS (Basic)
1.71CNYFY2025 · Dec 31, 2025EPS (Diluted)
1.69CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
66.16MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
66.16MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
113.13MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
103.85MCNYFY2025 · Dec 31, 2025Free Cash Flow
80.11MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
19.60MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
113.13MCNYFY2025 · Dec 31, 2025Other Non-cash Items
-154.50KCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-3.93MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-5.19MCNYFY2025 · Dec 31, 2025Capital Expenditures
-23.74MCNYFY2025 · Dec 31, 2025Purchase of Investments
-682.23MCNYFY2025 · Dec 31, 2025Sale of Investments
560.35MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-145.62MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-39.70MCNYFY2025 · Dec 31, 2025Other Financing Charges
11.50MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-28.20MCNYFY2025 · Dec 31, 2025Shares Outstanding
67.05MSharesUpdated Aug 29, 2026Float Shares
34.35MSharesUpdated Aug 29, 2026% Held by Insiders
45.66%vs all stocks
% Held by Institutions
21.52%vs all stocks
Total Cash (MRQ)
282.56MCNY42.03M · vs all stocks (USD)
Total Cash per Share (MRQ)
4.26CNYUpdated Aug 29, 2026Total Debt (MRQ)
9.33MCNY1.39M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0115xvs Medical Devices peers
Current Ratio (MRQ)
9.47xvs Medical Devices peers
Book Value per Share (MRQ)
12.24CNYUpdated Aug 29, 2026Total Assets
895.44MCNY133.19M · vs all stocks (USD)
Total Current Assets
375.19MCNYFY2025 · Dec 31, 2025Total Liabilities
97.38MCNYFY2025 · Dec 31, 2025Total Non-current Assets
520.24MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
45.81MCNYFY2025 · Dec 31, 2025Total Current Liabilities
51.57MCNYFY2025 · Dec 31, 2025Cash
29.59MCNYFY2025 · Dec 31, 2025Cash Equivalents
44.43MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
74.02MCNYFY2025 · Dec 31, 2025Other Short-term Investments
231.81MCNYFY2025 · Dec 31, 2025Accounts Receivable
25.03MCNYFY2025 · Dec 31, 2025Inventory
37.06MCNYFY2025 · Dec 31, 2025Accounts Payable
16.42MCNYFY2025 · Dec 31, 2025Other Current Liabilities
1.06MCNYFY2025 · Dec 31, 2025Common Stock (Book)
67.05MCNYFY2025 · Dec 31, 2025Retained Earnings
220.24MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
798.06MCNY118.70M · vs all stocks (USD)
Treasury Stock
7.89MCNYFY2025 · Dec 31, 202552-Week Low
44.88CNYUpdated Aug 29, 202652-Week High
92.00CNYUpdated Aug 29, 202652-Week Change
-33.10%vs all stocks
50-Day MA
56.01CNYUpdated Aug 29, 2026200-Day MA
61.77CNYUpdated Aug 29, 2026Avg 10-Day Volume
1.69MSharesUpdated Aug 29, 2026Avg 30-Day Volume
1.87MSharesUpdated Aug 29, 2026Diluted EPS (TTM)
1.82CNYUpdated Aug 29, 202610 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion Levels
Its gross margin and its cash margin are high for its industry, and its operating margin is high outright.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Operating Income Growing With Multi-Year Revenue Growth
Revenue up in each of five years, with operating income up in each of four.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Net Levels
Its gross and net margins are high for its industry, and its operating margin is high outright.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
ROE, ROA, And Operating ROA Elevated
It earns more on its equity than its industry does, and on its assets too — not on borrowing alone.
Reads
Is this company growing?
Multi-Year Revenue And Profit Growth
Revenue and earnings have both grown steadily across six years.
Reads
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is 39.4%, higher than 95% of its Medical Devices peers (median 7.3%)Significant
Operating margin: 0.39Industry median: 0.07Industry P95: 0.34Peers compared: 102
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Coordination data is not yet available for this stock.
Companies that share active interpretations — structural patterns currently present in both stocks.
NVIDIA Corporation
10 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingOperating Income Growing With Multi-Year Revenue GrowthMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsMulti-Year Revenue And Profit Growth
International Gemmological Institute
10 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingOperating Income Growing With Multi-Year Revenue GrowthMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsMulti-Year Revenue And Profit Growth
One Career Inc.
10 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingOperating Income Growing With Multi-Year Revenue GrowthMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsMulti-Year Revenue And Profit Growth